NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Making Headway in Clinical Program Expansion, Company Growth
Related Editorial Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to…







